Isotretinoin 5 mg daily for low-grade adult acne vulgaris – a placebo-controlled, randomized double-blind study
Article first published online: 26 APR 2013
© 2013 The Authors Journal of the European Academy of Dermatology and Venereology © 2013 European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology
How to Cite
Rademaker, M., Wishart, J.M. and Birchall, N.M. (2013), Isotretinoin 5 mg daily for low-grade adult acne vulgaris – a placebo-controlled, randomized double-blind study. Journal of the European Academy of Dermatology and Venereology. doi: 10.1111/jdv.12170
Conflict of interest
- Conflict of interest
- MR is on the speaker bureau for Douglas Pharmaceuticals Ltd., Auckland, New Zealand, but has no financial or other conflicts of interest. JMW and NMB declare no conflicts of interest.
- Funding sources
- This study was sponsored by Douglas Pharmaceuticals Ltd (Central Park Drive, Henderson, Auckland 0651, New Zealand). The sponsors assisted in the design of the study, as well as data monitoring. All data was processed and analysed by an independent contract research organisation (Datapharm Australia Pty Ltd, 56-56A Thompson Street, Drummoyne NSW 2047, Australia). The sponsor had no input in the interpretation of the data, preparation of the manuscript, in the review or approval of the final manuscript.
- Article first published online: 26 APR 2013
- Manuscript Accepted: 25 MAR 2013
- Manuscript Received: 18 NOV 2012
Despite acne persisting into adulthood in up to 50% of the population, very few therapeutic studies have been performed in this age group.
To assess the efficacy of 5 mg/day isotretinoin in adult acne.
An investigator initiated, industry-sponsored, randomized, double-blind, placebo-controlled, parallel-group clinical study of isotretinoin 5 mg/day in the treatment of low-grade adult acne for 16 weeks followed by an open-label phase of 16 weeks. Group 1 received 32 weeks of 5 mg isotretinoin/day; Group 2 first received 16 weeks of placebo, followed by 16 weeks open-label 5 mg isotretinoin/day. Patients were followed for a further 10 weeks off treatment. The primary end-point was the difference in acne lesion count and disability score after 16 weeks isotretinoin compared to placebo. Secondary end-points included differences in these counts/scores after 32 weeks of isotretinoin compared to baseline, and after 10 weeks off treatment, compared to end of treatment (week 32).
There were highly significant differences (P < 0.0001) in acne lesion count, Dermatology Life Quality Index and self-assessment after 16 weeks of isotretinoin, compared to placebo (both per protocol and intention to treat). Acne lesions fell significantly, within 4 weeks of 5 mg isotretinoin/day (Group 1) and continued to fall during 32 weeks of treatment [acne lesion count (mean ± SD): 11.3 ± 8.1 (baseline), 3.6 ± 5.5 (week 16), 1.3 ± 3.1 (week 32), P < 0.0001)]. There was a similar significant reduction in acne lesion count in Group 2, but only from week 20, 4 weeks after starting open-label 5 mg isotretinoin. Adverse effects were minimal.
Isotretinoin 5 mg/day is effective in reducing the number of acne lesions, and improving patients dermatologic quality of life, with minimal adverse effects.